<DOC>
	<DOCNO>NCT01824264</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , tolerability short-term safety LIK066 support dose selection phase 3 .</brief_summary>
	<brief_title>Dose-finding Study LIK066 Compared With Placebo Sitagliptin Evaluate Change HbA1c Patients With Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>1 . Confirmed diagnosis T2DM standard criterion 2 . Drugnaïve patient , define patient receive antidiabetic medication previously , 3 . Currently untreated patient , , diagnosis T2DM , receive antidiabetic medication 12 consecutive week , receive antidiabetic treatment within 12 week prior Visit 1 4 . Patients treat monotherapy least 8 consecutive week prior Visit 1 follow OADs : metformin , dipeptidyl peptidase4 inhibitor ( DPP4i ) , SU , glinide , alphaglucosidase inhibitor ( AGI ) 5 . HbA1c ≥ 7 ≤ 10.5 % Visit 1 drugnaïve/currently untreated patient 6 . HbA1c ≥ 7 ≤ 9.5 % Visit 1 patient treat OAD monotherapy 7 . HbA1c ≥ 7 ≤ 10.5 % Visit 199 ALL patient 8 . Age : ≥18 ≤ 75 year old Visit 1 9 . BMI ≥22 ≤45 kg/m2 Visit 1 1 . FPG ≥270 mg/dl ( 15 mmol/L ) drugnaïve/currently untreated patient ≥240 mg/dl ( 13.3 mmol/L ) patient OAD monotherapy Visit 1 2 . Insulin treatment &gt; 4 consecutive week last 6 month , corticosteroid use &gt; 7 day last 8 week , use growth hormone last 6 month , use weight control product &gt; 4 week last 6 month 3 . History acute metabolic complication , CV disease , type 1 diabetes mellitus , hepatic disorder , pancreatitis , chronic diarrhea 4 . Significant lab abnormality TSH outside normal range , UACR &gt; 300 mg/g creatinine , eGFR &lt; 60 ml/min/1.73m2 , hemoglobin &lt; 12 g/L men &lt; 11 g/L woman , hematuria 5 . ECG abnormalities include AV block , long QT syndrome QTc &gt; 450 msec men &gt; 470 msec woman 6 . History malignancy 7 . Women childbearing potential use effective method contraception Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Type 2 Diabetes mellitus , SGLT inhibitor , dose-response</keyword>
</DOC>